Breaking News Instant updates and real-time market news.

NCNA

NuCana

$11.40

-0.4 (-3.39%)

19:25
06/12/19
06/12
19:25
06/12/19
19:25

NuCana says FDA grants orphan drug designation for Acelarin

NuCana announced that the U.S. Food and Drug Administration has granted orphan drug designation for the Company's investigational drug, Acelarin, for the treatment of biliary tract cancer. Acelarin is a new chemical entity and is NuCana's ProTide transformation of gemcitabine. "We are pleased to have received orphan drug designation from the FDA for Acelarin in biliary tract cancer," said Hugh Griffith, NuCana's Founder and Chief Executive Officer. "There is a high unmet need for patients suffering from this cancer type. Our Phase Ib study of Acelarin combined with cisplatin showed an approximate doubling of the response rate expected with the standard of care, gemcitabine plus cisplatin, with several patients achieving significant reductions in their tumor volume as well as further tumor shrinkage over time. We believe Acelarin represents a potential significant advance in biliary tract cancer and we remain on track to open our global Phase III study in combination with cisplatin as a front-line treatment for patients with advanced biliary tract cancer in 2019."

NCNA NuCana
$11.40

-0.4 (-3.39%)

10/18/18
PIPR
10/18/18
INITIATION
Target $36
PIPR
Overweight
NuCana initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro started NuCana with an Overweight rating and $36 price target, stating that data for its lead product, Acelarin, have "strongly" pointed towards platform validation. He sees an opportunity for the drug in platinum-resistant ovarian cancer and sees the potential for it to "establish a new frontline standard of care in biliary tract cancer," Catanzaro tells investors.
10/21/18
PIPR
10/21/18
NO CHANGE
Target $36
PIPR
Overweight
NuCana updated Phase Ib data positive for acelarin in biliary cancer, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro notes that NuCana presented updated Phase Ib data for Acelarin plus cisplatin in 1st-line advanced BTC at ESMO this weekend. An ORR of 50% in 14 patients is consistent with the abstract and continues to suggest a near doubling of standard of care, he adds, highlighting that tumor reductions appear to be durable out to the 36-week assessment and the safety profile is unremarkable compared to gem/cis. The analyst maintains his positive outlook for the planned Phase III trial and the opportunity to establish a new standard of care for this sizable patient population. Catanzaro reiterates an Overweight rating and $36 price target on the shares.
03/10/19
PIPR
03/10/19
NO CHANGE
Target $35
PIPR
Overweight
NuCana shares 'significantly undervalued,' says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro is "incrementally more positive" around NuCana's "ambitious" development strategy for the ProTide platform after speaking to management. The analyst continues to believe that clinical data presented to date have fully supported ProTide's mechanism of action. Shares of NuCana are "significantly undervalued for the clear blockbuster potential" of NuCana's two lead assets, Catanzaro tells investors in a research note. He maintains an Overweight rating on the shares and trimmed his price target to $35 from $36.
06/02/19
PIPR
06/02/19
NO CHANGE
Target $35
PIPR
Overweight
NuCana pivotal BTC trial on-track to open in 2H19, says Piper Jaffray
Piper Jafrray analyst Joseph Catanzaro notes that NuCana provided a modest update to the Phase Ib studies looking at Acelarin in combination with platinum chemotherapy in ovarian and biliary tract cancer at ASCO with data largely consistent with prior updates. Enrollment into the pivotal Phase III BTC trial to evaluate Acelarin plus cisplatin is expected to begin in early 2H19, with final FDA sign-off on the protocol expected in the coming weeks, he notes. Catanzaro continues to believe that clinical data presented to date have fully supported Acelarin and the ProTide platform, and that Acelarin is well-positioned to establish a new standard of care in BTC. He reiterates an Overweight rating and $35 price target on the shares.

TODAY'S FREE FLY STORIES

VTR

Ventas

$69.65

1.05 (1.53%)

21:28
06/19/19
06/19
21:28
06/19/19
21:28
Upgrade
Ventas rating change at Stifel »

Stifel upgrades to Ventas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$197.87

-0.65 (-0.33%)

21:22
06/19/19
06/19
21:22
06/19/19
21:22
Initiation
Apple initiated at Deutsche Bank »

Apple initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

DELL

Dell Technologies

$53.39

1.88 (3.65%)

21:22
06/19/19
06/19
21:22
06/19/19
21:22
Initiation
Dell Technologies initiated at Deutsche Bank »

Dell Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

HPQ

HP Inc.

$20.63

0.1 (0.49%)

21:21
06/19/19
06/19
21:21
06/19/19
21:21
Initiation
HP Inc. initiated at Deutsche Bank »

HP Inc. initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

GNCA

Genocea

$3.84

-1.32 (-25.58%)

21:18
06/19/19
06/19
21:18
06/19/19
21:18
Syndicate
Genocea 10M share Secondary priced at $3.50 »

SVB Leerink and Stifel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

PSNL

Personalis

$0.00

(0.00%)

21:15
06/19/19
06/19
21:15
06/19/19
21:15
Syndicate
Personalis 7.922M share IPO priced at $17.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CYRX

Cryoport

$18.62

-0.08 (-0.43%)

21:13
06/19/19
06/19
21:13
06/19/19
21:13
Syndicate
Cryoport 3.75M share Spot Secondary priced at $17.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

VTR

Ventas

$69.65

1.05 (1.53%)

20:41
06/19/19
06/19
20:41
06/19/19
20:41
Upgrade
Ventas rating change at Stifel »

Ventas upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSY

Hershey

$137.94

-0.29 (-0.21%)

20:27
06/19/19
06/19
20:27
06/19/19
20:27
Downgrade
Hershey rating change at Piper Jaffray »

Hershey downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KR

Kroger

$23.64

-0.3 (-1.25%)

, DRI

Darden

$117.55

-0.39 (-0.33%)

20:25
06/19/19
06/19
20:25
06/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KR

Kroger

$23.64

-0.3 (-1.25%)

DRI

Darden

$117.55

-0.39 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 25

    Jun

  • 27

    Jun

DAL

Delta Air Lines

$56.38

0.33 (0.59%)

20:08
06/19/19
06/19
20:08
06/19/19
20:08
Periodicals
Breaking Periodicals news story on Delta Air Lines »

Delta working on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

SPY

SPDR S&P 500 ETF Trust

$293.02

0.69 (0.24%)

, SPX

S&P 500

$0.00

(0.00%)

20:00
06/19/19
06/19
20:00
06/19/19
20:00
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

Trump not planning to…

SPY

SPDR S&P 500 ETF Trust

$293.02

0.69 (0.24%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARZGY

Generali

$0.00

(0.00%)

19:22
06/19/19
06/19
19:22
06/19/19
19:22
Downgrade
Generali rating change at JPMorgan »

Generali downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GO

Grocery Outlet

$0.00

(0.00%)

19:00
06/19/19
06/19
19:00
06/19/19
19:00
Syndicate
Grocery Outlet 17.19M share IPO priced at $22.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

WIX

Wix.com

$145.83

1.19 (0.82%)

18:57
06/19/19
06/19
18:57
06/19/19
18:57
Hot Stocks
Wix.com CEO: Q1 was very good for us »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AOBC

American Outdoor Brands

$9.17

0.13 (1.44%)

, ORCL

Oracle

$52.69

-0.19 (-0.36%)

18:44
06/19/19
06/19
18:44
06/19/19
18:44
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

AOBC

American Outdoor Brands

$9.17

0.13 (1.44%)

ORCL

Oracle

$52.69

-0.19 (-0.36%)

JSYN

Jensyn Acquisition

$5.00

-5.02 (-50.10%)

ABEO

Abeona Therapeutics

$4.90

-0.09 (-1.80%)

PIR

Pier 1 Imports

$0.67

-0.0059 (-0.87%)

SCS

Steelcase

$17.80

0.235 (1.34%)

LAND

Gladstone Land

$12.29

0.39 (3.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 19

    Jun

  • 20

    Jun

  • 24

    Jun

  • 26

    Jun

  • 26

    Jun

  • 10

    Jul

  • 20

    Jun

TMUS

T-Mobile

$78.28

1.79 (2.34%)

, S

Sprint

$7.46

0.24 (3.32%)

18:39
06/19/19
06/19
18:39
06/19/19
18:39
Periodicals
T-Mobile readies for Boost auction if Dish talks fall through, Reuters says »

T-Mobile (TMUS) is…

TMUS

T-Mobile

$78.28

1.79 (2.34%)

S

Sprint

$7.46

0.24 (3.32%)

DISH

Dish

$38.90

-0.18 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$200.57

-1.1 (-0.55%)

18:39
06/19/19
06/19
18:39
06/19/19
18:39
Hot Stocks
Zebra Technologies Chief of Product sells 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$200.57

-1.1 (-0.55%)

18:23
06/19/19
06/19
18:23
06/19/19
18:23
Hot Stocks
Zebra Technologies CEO sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$250.25

4.6 (1.87%)

, DVA

DaVita

$51.27

1.51 (3.03%)

18:13
06/19/19
06/19
18:13
06/19/19
18:13
Hot Stocks
FTC approves UnitedHealth's acquisition of DaVita Medical with conditions »

Healthcare provider and…

UNH

UnitedHealth

$250.25

4.6 (1.87%)

DVA

DaVita

$51.27

1.51 (3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

SRRK

Scholar Rock

$17.11

-2.835 (-14.21%)

18:11
06/19/19
06/19
18:11
06/19/19
18:11
Syndicate
Scholar Rock 3M share Secondary priced at $15.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

QDEL

Quidel

$58.80

1.7 (2.98%)

18:01
06/19/19
06/19
18:01
06/19/19
18:01
Hot Stocks
Quidel receives 510k clearance for Triage TOX Drug Screen »

Quidel Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$53.39

1.88 (3.65%)

, HPQ

HP Inc.

$20.63

0.1 (0.49%)

17:59
06/19/19
06/19
17:59
06/19/19
17:59
Periodicals
Dell, HP, Intel, Microsoft express opposition to Trump tariffs, Bloomberg says »

Dell Technologies (DELL),…

DELL

Dell Technologies

$53.39

1.88 (3.65%)

HPQ

HP Inc.

$20.63

0.1 (0.49%)

INTC

Intel

$47.08

-0.29 (-0.61%)

MSFT

Microsoft

$135.63

0.43 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 23

    Jun

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

  • 09

    Jul

  • 09

    Jul

  • 10

    Jul

  • 25

    Jul

  • 06

    Aug

ORCL

Oracle

$52.69

-0.19 (-0.36%)

17:54
06/19/19
06/19
17:54
06/19/19
17:54
Hot Stocks
Oracle says 20% of Autonomous Database customers new to company »

Says plans to launch free…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

CB

Chubb

$149.48

1.37 (0.92%)

17:54
06/19/19
06/19
17:54
06/19/19
17:54
Hot Stocks
Chubb CEO sells 215.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.